Regeneron Pharmaceuticals Appoints New CFO and Controller

Details

announced the appointment of Christopher Fenimore as its new Senior Vice President, Finance and Chief Financial Officer, succeeding Robert E. Landry who is retiring. Additionally, Jason Pitofsky was appointed as Vice President, Controller. Both appointments will take effect after the Company files its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

Items reported

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.